FTRE
Fortrea Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.93
−1.73%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- $0.23
- Revenue estimate
- $670.5M
Latest reported
- Last report date
- Jul 29, 2026
- EPS actual
- $0.23
- EPS estimate
- $0.18
- Revenue actual
- $678.2M
- Revenue estimate
- $647.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +98.0%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $22
- PT range
- $16 – $26
- Analysts
- 8
5 Buy3 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 29, 2026 | $0.18 | $0.23 | Beat 27.49% | $678.2M |
| May 5, 2026 | $0.03 | $0.16 | Beat 433.33% | $636.5M |
| Feb 26, 2026 | $0.16 | $0.09 | Miss -43.75% | $660.5M |
| Nov 5, 2025 | $0.16 | $0.12 | Miss -25.00% | $701.3M |
| Aug 6, 2025 | $0.06 | $0.19 | Beat 216.67% | $710.3M |
| Mar 3, 2025 | $0.36 | $0.18 | Miss -50.00% | $697.0M |
| Nov 8, 2024 | $0.27 | $0.23 | Miss -14.81% | $674.9M |
| Mar 11, 2024 | $0.23 | $0.19 | Miss -17.39% | $775.4M |
| Nov 13, 2023 | $0.18 | $0.24 | Beat 33.33% | $776.4M |
| Aug 14, 2023 | $0.39 | $0.52 | Beat 33.33% | $793.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026